![]() | |
Clinical data | |
---|---|
Pronunciation | /nɜːrˈmætrəlvɪər/ nur-MAT-rəl-veer or /ˌnɜːrməˈtrɛlvɪər/ NUR-mə-TREL-veer |
Other names | PF-07321332 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C23H32F3N5O4 |
Molar mass | 499.535 g·mol−1 |
3D model (JSmol) | |
Melting point | 192.9 °C (379.2 °F) [3] |
| |
|
Nirmatrelvir is an antiviral medication developed by Pfizer which acts as an orally active 3C-like protease inhibitor.[3][4][5][6][7] It is part of a nirmatrelvir/ritonavir combination used to treat COVID-19 and sold under the brand name Paxlovid.[8]
Owen
was invoked but never defined (see the help page).